E13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. E induces cell death through profound alterations in the plasmatic membrane of tumor cells, while C targets the DNA in a cell cycle independent manner. In vitro experiments showed a synergistic effect between E and platinum compounds in different cell lines. Objectives: To identify the maximum tolerated dose (MTD) and the recommended dose (RD) of C given on day (d) 1 followed by E as a 3-hour i.v. infusion on d1 and d8, every three weeks, as well as safety and feasibility, pharmacokinetic analysis and antitumor activity. Methods: Pts with advanced solid tumors for whom no standard therapy is available were recruited. A classical 3+3 successive cohort escalation design was followed. Results: The median age of the 15 pts included was 59 (25-73) years, they had received a median 6 prior lines of therapy, and 10 were males. Main tumor types were colorectal and head and neck (n=4, each). After 3 evaluable pts we...